Organogenesis

Update in progress

ORGO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and markets products for advanced wound care, surgical, and sports medicine in the United States. Its portfolio includes amnion/chorion placental allografts (Affinity, Novachor), Apligraf, Dermagraft, NuShield, PuraPly AM/SX, CYGNUS Dual/VIA Matrix/SimpliMax, PuraPly MZ, PuraForce, FortiShield, TransCyte, and ReNu (Phase 3) for knee osteoarthritis. Headquartered in Canton, MA, it serves hospitals, wound care centers, and clinics via direct and partner channels.

Company score

Sentiment: 0.53; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.31; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive